Each blood transfusion exposes the recipient to the hazards of immunisation to histocompatibility antigens as well as white cell and platelet antigens. As the number of transfusions received by a patient increases so too does the likelihood of the development of antibodies which may by their multispecific character effectively prevent lifesaving therapy in the future. Special steps can and should be taken to minimise the risks of immunisation in the group of patients who will be dependent on long term transfusion therapy. An extension of knowledge about the antigenic systems of leucocytes and platelets, including HLA, and the introduction of more specific tests for the detection of antibodies directed against them should assist in the provision of more appropriately matched blood components.
The plasma membrane surface of leucocytes and platelets is, like its red cell counterpart, covered with a mosaic of antigens. Some are shared by all the cells of the body, some are common to a number of blood cells, whilst some are specific to one cell type. All appear to have the ability to provoke the formation of antibodies if cells carrying any of these antigens are introduced into the circulation of recipients who lack them. The clinical effects of such antibodies vary depending on the target cell or cells to which they are directed, but as the use of transfusion becomes more widespread, their sequelae assume greater importance and warrant a very clear attempt on our part to prevent their development, especially in patients for whom long term transfusion therapy is a critical life support.
The antigens present on leucocytes and platelets and their distribution between various cell types is shown in Table 1 . platelets 3 is only slightly reduced but because of the high degree of red cell contamination in both granulocyte and platelet concentrates, ABO compatible infusions are normally used.
A variety of other red cell antigens are also expressed on leucocytes and platelets. The P antigens are, like the ABO and HLA-A, B, C antigens, ubiquitous; the Lewis antigens are adsorbed from the plasma. Jk a Jk b and U are present on granulocytes as well as red cells but not on lymphocytes or platelets. 4 ,5 There is no evidence that antibodies to these antigenic systems compromise the survival of transfused white cells or platelets. The two alleles of the Five system, 5a and 5b, have been found on all cells and tissues studied. This system is not linked to HLA, does not appear to be involved in transplant rejection and is largely of theoretical interest. 6 The HLA System
The HLA system, the most polymorphic genetic system known in man, includes four currently recognised allelic series of antigens, HLA-A, -B, -C and -D each with many alleles ( Table 2 ). The HLA-A, B, C antigens are present on all body cells and are present in large amounts on both leucocytes and platelets and in small amounts in plasma. HLA typing carried out by the standard microcytotoxicity test utilising peripheral blood lymphocytes is thought to mirror the expression of the antigens on all other body cells with one exceptionapproximately 20OJo of individuals positive for HLA-B12 by lymphocyte typing fail to express this antigen on their platelets. 7 It seems likely that some variation in expressivity of other HLA antigens on different tissues occurs from one individual to another although not to the degree demonstrable for B12. The HLA-A and -B antigens are potent in provoking antibody formation and are clinically thought to be the most relevant to blood transfusion practice at the present time. The HLA-C series antigens seem to be poorly immunogenic and the HLA-D antigens are of little relevance in this context because they are restricted in distribution to B (bone marrow derived) lymphocytes, macrophages and endothelial cells.
Antibodies to the HLA antigens are not naturally occurring and are provoked by transfusion, pregnancy or tissue grafts. 2  Currently recognised antigens of the HLA system   HLA-A  HLA-B  HLA-C   HLA-AI  HLA-B5  HLA-Bw42 HLA-Cwl  HLA-A2 HLA-B7 HLA-Bw44 HLA-Cw2 HLA-A3
Immunisation may follow the transfusion of
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HLA-BI2 HLA-Bw46 HLA-Cw4 HLA-IO HLA-BI3 HLA-Bw47 HLA-Cw5 HLA-AII HLA-BI4 HLA-Bw48 HLA-Cw6 HLA-AwI9 HLA-BI5
HLA-Bw49 HLA-Aw23 HLA-BwI6 HLA-Bw50 HLA-Aw24 HLA-B17
HLA-Bw51 HLA-A25
HLA-BI8 HLA-Bw52 HLA-A26 HLA-Bw21 HLA-Bw53 HLA-A28
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HLA-Bw4 HLA-Aw30 HLA-Bw35 HLA-Bw6 HLA-Aw31 HLA-B37 HLA-Aw32 HLA-Bw38 HLA-AwJ3 HLA-Bw39 HLA-Aw34 HLA-B40 HLA-Aw36 HLA-Bw41 HLA-Aw43 9 have shown that 50% of patients with leukaemia will become immunised to HLA within 4-6 weeks of commencing regular platelet infusions. Van Rood et al. 10 believe that it is the leucocytes in platelet concentrates which are responsible. Although it is believed that immunosuppressive therapy can delay immunisation it will not prevent it. 9 Multiparous women are a rich source of antibodies. Unlike the antibodies directed against red cell antigens these are frequently found in the first pregnancy as early as 26 weeks gestation, and are present in 10% of such women by the end of the third trimester .11 The antibodies frequently disappear within 6 months of delivery but the incidence of more persistent antibodies increases with parity to reach 55 % by the end of the third pregnancy. 12 Thereafter it tends to decline. Antibodies to the HLA antigens are more likely to be found in women who are also immunised to red cell antigens. The majority of antibodies found after pregnancy or transfusion are multi specific , i.e. react with the cells of a majority of individuals, often 90% or more. II , 13 This is so even in primiparae. The reason is not clear but may relate to the extensive degree of cross-reactivity which exists between antigens of the HLA system ( Figure 1 ). When antibody is directed against a single specificity the specificity is most commonly HLA-A2 or -B7. FIGURE 1 ,-One HLA Cross Reactive Group (cross reactive antigens are joined by lines).
Detection of HLA antibodies
Anti-HLA antibodies may be detected by leucoagglutination,14 lymphocytotoxicity15 or platelet complement fixation 16 (Table 3) . Leucoagglutination was the first test used and is probably the most sensitive but it has been largely abandoned because of poor reproducibility. The platelet complement fixation test is insensitive and is an unreliable method for antibody screening. The most widely used test is the microlymphocytotoxicity test. This is based on the ability of anti-HLA antibodies to kill lymphocytes having the corresponding antigen, in the presence of rabbit complement. Cell death is demonstrated by the addition of a dye which is taken up by the dead and damaged cells and the test is read microscopically. Screening is carried out using the lymphocytes of a standard panel of normal individuals (about 40) to encompass all known HLA-A, B, C antigens, and of patients suffering from chronic lymphocytic leukaemia as a source of B lymphocytes, which are selected to include all known HLA-D antigens. For convenience such panel cells are stored in liquid nitrogen. Even when it is not possible to define the specificity of the antibody detected, an assessment of its reactivity, frequency and strength can be made.
The lymphocytotoxicity test is also used as a crossmatching procedure when donors for leucopheresis and plateletpheresis are being sought for a particular patient. The test is set up using the recipient's serum and the potential donor's lymphocytes. An autocontrol is also included.
Clinical complications of HLA antibodies
Two possible complications may arise in patients receiving transfusions due to the presence of anti-HLA antibodies. The first is a febrile non-haemolytic transfusion reaction which is unpleasant for the patient, worrying for the medical staff and frequently results in cessation of the transfusion. The second complication, which may be critical for patient survival, is the rapid destruction of infused granulocytes or platelets before they can exert any beneficial effect. This manifests clinically as a febrile reaction during infusion and by a failure of the granulocyte or platelet count to rise.
In more than 60070 of cases of febrile nonhaemolytic transfusion reactions evidence of immunisation to the HLA antigens is found. 17 About 60% of detected antibodies are multispecific. 13 In ill patients the autocontrol may be positive but in general it is not as strong as the reactions obtained with allogeneic cells.
If the patient is resistant to infusions of platelet and leucocyte concentrates from random donors the antibody responsible is often found to be multispecific. In this worrying situation the successful management of the patient will depend on the availability of HLA-matched donors who demonstrate a negative lymphocytotoxicity crossmatch with the patient's serum. In practice this will mean an HLA-matched, ABO-compatible relative.
There is no evidence that anti-HLA antibodies are of any significance in pregnancy. Although most are IgG and capable of crossing the placenta, they are presumably adsorbed harmlessly by the placenta or the baby's tissues. Indeed it has been suggested that such antibodies may play a beneficial role in the maintenance of normal pregnancy. 18 A paradox exists as to their role in patients receiving kidney transplants. Anti-HLA-A, B, C antibodies specific for donor antigens will rapidly destroy a transplanted kidney and a meticulous lymphocytotoxicity crossmatch test is carried out prior to transplantation to avoid such an occurrence. However, there is considerable evidence that renal graft survival is better in patients who have been transfused. 19 This may be due to the induction of nonspecific tolerance by transfusion or by the production of "protective" antibody not detected by the usual crossmatch procedures. 20 
HLA antigens on red cells
Several studies have suggested that HLA antigens may be expressed on red cells,21 and strong correlation has been shown with the Oonna-Bennett-Goodspeed (OBg) system. Antibodies directed against OBg red cell antigens often appear to be also directed against the HLA antigens of positively reacting individuals, especially those carrying A28(Bgc), B7(Bga) and BI7(Bgh); but this is not a consistent finding and anti-OBg antibodies do not behave like classical IgM or IgG antibodies. They can be neutralised by pooled normal serum, they react weakly by the indirectantiglobulin test or by automated screening methods and do not show a classical fall-off in activity with titration, and they are readily absorbed by appropriate platelets. 22 ,23 These anomalies raise the question of whether OBg antigens really are HLA antigens expressed on red cells, whether they are adsorbed like Lewis antigens from the plasma or whether they are part of an antigen system linked to or crossreactive with HLA. This problem has not yet been resolved. There is little evidence that anti-OBg antibodies provoke haemolytic transfusion reactions or haemolytic disease of the newborn but they may produce difficulties in crossmatching red cells for transfusion.
Granulocyte-specijic Antigens
Six granulocyte-specific antigens have been identified. 24 Apart from the alleles NAl and NA2 they appear to belong to independent systems each represented by a single allele. Antibodies directed against these antigens are associated with both allo-immune neonatal neutropenia and auto-immune neutropenia. In the former condition the maternal antibodies cross the placenta and the resultant severe neutropenia is usually manifested by infection in the neonate. Antibody is detected in the maternal serum but may also be found in the serum of the affected child. Antibodies which behave in this way seem to have been provoked by pregnancy rather than by transfusion. Verheught et al. 25 have shown that granulocyte-Anaesthesia and Intensive Care, Vol. VIII, No. 2, May, 1980 specific antibodies were detectable in the serum of 2070 of 198 women at term compared with 33% with anti-HLA antibodies. This low but significant level of immunisation appears to have little significance in pregnancy since alloimmune neonatal neutropenia in florid form is an excessively rare disorder.
The incidence of granulocyte-specific antibodies following transfusion and their contribution to febrile non-haemolytic transfusion reactions is unknown, because of the swamping effect of anti-HLA antibodies. However, mar ked pulmonary infiltration associated with dyspnoea, cyanosis and collapse has been reported following the infusion of blood containing high titre leucoagglutinins. It is not clear whether the antibodies responsible are granulocyte-specific or directed against antigens of the HLA system. 26
Detection of granulocyte-specijic antibodies
Two tests are available for the detection of granulocyte-specific antibodies ( Table 3) : Leucoagglutination and the Indirect Granulocyte Fluorescence Technique. A number of different leucoagglutination techniques have been described. 14 The most commonly applied is a microtest utilising leucocytes prepared from either EOT A or defibrinated blood. This test suffers from poor reproducibility but has been widely used for many years, and was reliable enough to establish the existence of such specific anti genic systems. The Indirect Immunofluorescence test was described only in 1977 and appears to be reliable, sensitive and reproducible. 25 However, it has not yet had widespread use. Leucocytes are pre-fixed with paraformaldehyde and immunoglobulin class-specific or composite fluorescein-Iabelled antiglobulin serum is used to detect antibody on the cell surface. Unfortunately both the leucoagglutination and the fluorescent technique recognise anti-HLA as well as granulocyte-specific antibodies and if the two co-exist, as must often be the case, careful absorption studies would be required to determine their specific nature.
Platelet-specific antigens
Four platelet-specific antigen systems have been described. 16 Three (PLA, PLE and Ko) each have two alleles but the fourth, Ouzo, has a single allele. Platelet-specific antigens have 
Plalelel-specijic
Thromboagglutination Antiglobulin consumption Platelet complement fixation 14C serotonin uptake/release 125 1 labelled indirect antiglobulin Indirect immunotluorescence generated interest because of two rare but dramatic clinical conditions associated with them allo-immune neonatal thrombocytopenia and post-transfusional purpura. Immunisation to platelet antigens can follow both pregnancy and transfusion but it is of interest that almost all reported cases of alloimmune neonatal thrombocytopenia and posttransfusional purpura have appeared to be the result of immunisation during pregnancy. Although allo-immune neonatal purpura is rare it can have devastating effects. The neonate may present with a generalised purpuric rash within minutes or hours of birth or may be born with brain damage due to intra-cerebral haemorrhage. Thrombocytopenia persists for several weeks and antibodies specific for the infant's platelet antigens are present in the maternal serum although they are not generally detected in the baby. The antibody most frequently involved is anti-PLAI but anti-PLEl and anti-Duzo have been implicated in several cases as well as a variety of HLA antibodies. 16 The absence of thrombocytopenia and the presence of specific antibody in the mother distinguishes this syndrome from neonatal thrombocytopenia secondary to maternal ITP (Idiopathic Thrombocytopenia Purpura).
Post-transfusional purpura is no less dramatic in its presentation with the sudden appearance of florid purpura one week or more after transfusion. This may be associated with clinical bleeding. In all but one reported case the reaction was due to anti-PLAl. Since the antibody may become undetectable after the attack, it is possible that all cases are in fact due to this antibody. Several characteristics of the syndrome are perplexing. Although 2070 of random transfusions involve incompatibility for the PLAl antigen, in only a very few cases does post-transfusional purpura occur. Secondly, the patient's own PLAl negative platelets are destroyed as well as the transfused platelets and this destruction continues for some weeks. Antigen-antibody complexes may be responsible for the destruction of autologous platelets or the antibody may cross-react with other antigens on the patient's platelets. 16 The frequency with which platelet-specific antibodies follow transfusion and their role in the immune destruction of transfused platelets is largely unknown, because of the overwhelming presence of anti-HLA antibodies. Even if the complex absorption studies necessary to define these antibodies in the presence of anti-HLA immunisation were carried out it would be difficult to assess the relative contribution of each. However, immune destruction of HLA identical platelets has been described and is presumably due to the activity of platelet-specific antibodies. 27 
Detection of platelet-specific antibodies
Many different tests have been used for the detection of platelet-specific antibodies (Table  3 ) -the variety of tests available indicating that most have been unsatisfactory (reviewed by Svejgaard 16 and Heinrich et al. 28 ) . They include thrombo-agglutination, antiglobulin consumption, platelet micro-complement fixation, C l4 -serotonin uptake and release, and indirect immunofluorescence. Problems arise because many platelet antibodies fail to produce agglutination or to fix complement. The most recently introduced technique, the Platelet Suspension Immunofluorescence test using para formaldehyde-fixed platelets and fluorescein labelled antiglobulin serum appears to hold great promise. 29 However, it also detects anti-HLA antibodies.
Management of the immunised patient
Two major clinical problems arise because of the activity of antibodies directed against leucocytes and platelets -febrile nonhaemolytic transfusion reactions and immune destruction of leucocyte and platelet infusions in patients in whom such therapy may be lifesaving. The prevention of febrile transfusion reactions in patients who require simply red cell replacement is not difficult and involves the use of leucocyte and platelet-free packed red cells. It has been shown that the severity of the reaction is dependent on both the antibody activity and the number of cells infused. Triple washed red cells are free of all but 5-10070 of leucocytes and platelets and will be suitable for most patients. If reactions still occur then the use of frozen washed red cells which are virtually leucocyte and platelet free is indicated. Both these products have a greatly decreased shelf life and must be used as soon as possible after preparation. The use of blood which has been passed through special filters to remove both leucocytes and platelets has recently been advocated for use in such patients. 3o
The provision of effective leucocyte and platelet transfusions is a greater problem. When platelets and buffy coats from random donors are no longer effective, recourse should be made to special donations obtained by leucoor plateletpheresis. The most effective donors will be close relatives of the patient, especially siblings, and a cross match should be done to ensure that the recipient's antibody is not directed towards the donor's antigens. At present a lymphocytotoxicity test is most appropriate but if the indirect fluorescence test proves to be reliable a direct cross match against granulocytes and platelets will be available. Clinical results can be improved in some patients by selecting HLA matched donors,3l but in recipients with multi specific antibodies donor selection will need to be based on a negative cross match.
Prevention of immunisation
The effective management of an increasing number of diseases depends on the availability of haematological supportive therapy, especially leucocyte and platelet concentrates, and in the patient's ability to benefit from such therapy. In patients suffering from diseases such as aplastic anaemia, leukaemia and certain congenital disorders, the development of immunisation to HLA and other leucocyte and platelet antigens can close the doors to effective therapy, and in such patients steps should be taken early in the clinical course of their disease to minimise the risks of immunisation ( washed packed cells should be used if only red cell replacement is required. The use of single donations obtained by leucopheresis and plateletpheresis may delay the development of immunisation. Van Rood et al. IO have suggested that the removal of leucocytes from platelet concentrates may delay the development of immunisation by up to 18 months. Such platelet concentrates, prepared by repeated saline washing, place an almost intolerable work load on the transfusion service and their use should be restricted to a highly selected group of patients. Diepenhorst et al. 30 have shown that the filtration of blood through cotton wool filters also reduces the proportion of leucocytes and platelets by more than 90070 and is effective in delaying immunisation. Recent developments in Australia suggest that much of the blood available in the future could be of this type, "poorly immunogenic" bloodY
